HomeCompareDPDW vs ABBV

DPDW vs ABBV: Dividend Comparison 2026

DPDW yields 338.98% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DPDW wins by $3498.92M in total portfolio value
10 years
DPDW
DPDW
● Live price
338.98%
Share price
$0.59
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3499.02M
Annual income
$2,214,135,232.96
Full DPDW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DPDW vs ABBV

📍 DPDW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDPDWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DPDW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DPDW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DPDW
Annual income on $10K today (after 15% tax)
$28,813.56/yr
After 10yr DRIP, annual income (after tax)
$1,882,014,948.02/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DPDW beats the other by $1,881,993,892.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DPDW + ABBV for your $10,000?

DPDW: 50%ABBV: 50%
100% ABBV50/50100% DPDW
Portfolio after 10yr
$1749.56M
Annual income
$1,107,080,002.36/yr
Blended yield
63.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DPDW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DPDW buys
0
ABBV buys
0
No recent congressional trades found for DPDW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDPDWABBV
Forward yield338.98%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3499.02M$102.3K
Annual income after 10y$2,214,135,232.96$24,771.77
Total dividends collected$3375.01M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DPDW vs ABBV ($10,000, DRIP)

YearDPDW PortfolioDPDW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$44,598$33,898.31$11,550$430.00+$33.0KDPDW
2$189,011$141,290.37$13,472$627.96+$175.5KDPDW
3$761,865$559,624.20$15,906$926.08+$746.0KDPDW
4$2,923,363$2,108,166.74$19,071$1,382.55+$2.90MDPDW
5$10,688,064$7,560,066.09$23,302$2,095.81+$10.66MDPDW
6$37,268,236$25,832,007.23$29,150$3,237.93+$37.24MDPDW
7$124,058,027$84,181,014.50$37,536$5,121.41+$124.02MDPDW
8$394,630,578$261,888,489.26$50,079$8,338.38+$394.58MDPDW
9$1,200,826,208$778,571,489.70$69,753$14,065.80+$1200.76MDPDW
10$3,499,019,276$2,214,135,232.96$102,337$24,771.77+$3498.92MDPDW

DPDW vs ABBV: Complete Analysis 2026

DPDWStock

Koil Energy Solutions, Inc., an energy services company, provides equipment and support services to the energy and offshore industries. It offers engineering and project management services, including the design, installation, and retrieval of subsea equipment and systems; connection and termination operations services; well-commissioning services; and construction support services. The company also provides project management and engineering; spooling; testing and commissioning; storage management; and refurbishment and repurposing of recovered subsea equipment, as well as support services for offshore interventions. In addition, it offers loose steel tube flying lead and umbilical hardware products, as well as riser isolation valves and subsea isolation valve services. Further, the company provides installation aids, including flying lead installation systems, tensioners, lay chutes, buoyancy modules, clump weights, mud mats, pumping and testing skids, control booths, fluid drum carriers, under-rollers, carousels, running and parking deployment frames, termination shelters, pipe straighteners, subsea deployment basket system, horizontal drive units, and rapid deployment cartridges. It serves energy companies, subsea equipment manufacturers, subsea equipment installation contractors, offshore drilling contractors, engineering and construction companies, and other companies involved in maritime operations. The company was formerly known as Deep Down, Inc. and changed its name to Koil Energy Solutions Inc. in April 2022. Koil Energy Solutions Inc. was founded in 1997 and is headquartered in Houston, Texas.

Full DPDW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DPDW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DPDW vs SCHDDPDW vs JEPIDPDW vs ODPDW vs KODPDW vs MAINDPDW vs JNJDPDW vs MRKDPDW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.